Executive Summary
Across the 7 filings in the USA S&P 500 Energy intelligence stream, key themes include proactive capital allocation with debt refinancings (Targa's $1.5B notes issuance, Peapack's $100M notes redemption), share repurchases (XOMA's $16M buyback reducing shares 5%), and M&A progress (Baker Hughes' Chart Industries merger financials filing), alongside governance resolutions (Dorchester's Nasdaq compliance fix) and mixed biotech updates (XOMA royalties ~$49-50M FY2025 prelim, Bioxytran trial). Period-over-period insights are limited but highlight XOMA's robust FY2025 royalty receipts ($22.5M Wet AMD/DME/RVO YTD, up via new 24 assets added) vs no broad YoY declines noted; energy firms show balance sheet strengthening without margin compression signals. Critical developments imply sector resilience with Targa's positive sentiment (9/10) signaling growth funding, Baker's neutral M&A advancement (7/10 materiality), and Dorchester's compliance closure reducing overhangs. Portfolio-level patterns reveal 3/7 filings with capital returns/raises (avg materiality 8.7/10), favoring bullish positioning amid stable operations. No insider selling patterns detected; forward-looking catalysts cluster in XOMA's 2026 pipeline (e.g., Seralutinib data, ersodetug approvals). Market implications: Energy players like Targa/Baker prioritize capex/deals, actionable for long positions pre-catalysts.
Tracking the trend? Catch up on the prior S&P 500 Energy Sector SEC Filings digest from February 26, 2026.
Investment Signals(10)
- XOMA Royalty Corp↓(BULLISH)▲
Preliminary FY2025 royalty/milestone cash receipts ~$49-50M (incl. $22.5M Wet AMD/DME/RVO at 0.5% royalty), $133M cash position (82M unrestricted), repurchased 648k shares for $16M reducing OS to 11.9M (-5% shares), added 24 assets enhancing >100 portfolio
- XOMA Royalty Corp↓(BULLISH)▲
>$140M milestones received since 2017, >$2B future potential from commercial portfolio (r/rpLGG $8.5M mid-single digit YTD), mixed sentiment offset by strong liquidity
- Peapack-Gladstone Financial↓(BULLISH)▲
Intent to redeem $100M 3.50% subordinated notes due 2030 at 100% principal + interest on ~March 2, 2026, remains well-capitalized post-redemption, positive sentiment 8/10
- Targa Resources Corp↓(BULLISH)▲
Completed $1.5B senior notes offering ($750M 4.350% due 2031, $750M 6.050% due 2056), proceeds for debt repay/capex/working capital, positive sentiment 9/10
- Baker Hughes Co↓(BULLISH)▲
Filed audited financials of Chart Industries (2025/2024) + Deloitte consent for July 2025 merger agreement, advancing Class A stock/5.125% notes registration, materiality 7/10
- Dorchester Minerals↓(BULLISH)▲
Appointed A. Troy Sturrock to Board/Advisory Committee Feb 11, 2026, resolving Nasdaq audit committee deficiency (from 3 to 2 members post-Oct 2025 death), compliance confirmed Feb 27
- Bioxytran Inc↓(BULLISH)▲
Phase 1b/2a ProLectin-M trial showed 90% Day-5 viral clearance (16,800mg dose) vs 20% placebo (p=0.001), favorable safety (no SAEs), materiality 9/10 despite mixed sentiment
- Peapack-Gladstone Financial (8-K/A)↓(BULLISH)▲
New directors D’Erasmo (Risk/Tech Committees) and Walsh (Risk/Compensation) appointed Feb 26, 2026, enhancing governance post-Dec 2025 original filing
- XOMA Royalty Corp↓(NEUTRAL-BULLISH)▲
G&A up $1M YoY due to litigation but offset by $133M cash and portfolio growth, no YoY revenue decline in prelim FY2025 receipts
- Targa Resources Corp↓(BULLISH)▲
Notes guaranteed by subsidiaries under 2022 indenture supplemented March 2, 2026, strong execution vs sector peers with no similar raises noted
Risk Flags(8)
- XOMA Royalty Corp/Litigation↓[HIGH RISK]▼
Ongoing litigation vs Janssen Biotech over TREMFYA IP breach/unjust enrichment, G&A expenses rose $1M (uncertain outcome, continued legal costs expected)
- XOMA Royalty Corp/Operational↓[MEDIUM RISK]▼
Mixed sentiment (8/10 materiality) from litigation overhang despite FY2025 receipts ~$49-50M and strong cash
- Bioxytran Inc/Clinical↓[HIGH RISK]▼
Primary endpoint (Day-7 viral clearance) not differentiated across arms due to natural resolution; lower doses only 20-40% clearance vs 90% high dose
- Bioxytran Inc/Trial↓[MEDIUM RISK]▼
Mixed sentiment 9/10 materiality, conducted in India (RT-PCR patients), potential regulatory hurdles despite Day-5 p=0.001
- Dorchester Minerals/Governance↓[MEDIUM RISK]▼
Prior Nasdaq non-compliance (Nov 2025 notification) from audit committee drop to 2 members (Rules 5615(a)(4)(C)/5605(c)(2)(A)), resolved but signals board instability
- Peapack-Gladstone Financial/Debt↓[LOW-MEDIUM RISK]▼
Redeeming $100M notes but highlights existing subordinated debt load, even if well-capitalized post-event
- Baker Hughes Co/M&A↓[MEDIUM RISK]▼
Neutral sentiment 7/10 on Chart merger financials filing (no metrics disclosed), potential integration risks post-July 2025 agreement
- XOMA Royalty Corp/Cash↓[LOW RISK]▼
$51M restricted cash portion of $133M total, limits flexibility amid litigation
Opportunities(8)
- XOMA Royalty Corp/Portfolio Expansion↓(OPPORTUNITY)◆
Added 24 assets in 2025 (from KNTE, EPIX etc.), >$2B future potential, $49-50M FY2025 receipts + $140M milestones since 2017, undervalued royalty play
- XOMA Royalty Corp/2026 Catalysts↓(OPPORTUNITY)◆
Seralutinib Ph2b/3 PAH data, ersodetug EMA/Japan decisions (cHI/FAP), REC-4881 Ph1/2 data, launches (ersodetug THI, volixibat PSC, rilvegostomig lung)
- Targa Resources Corp/Capital Raise↓(OPPORTUNITY)◆
$1.5B notes proceeds for capex/debt repay/securities repurchase, positions for growth in energy midstream vs peers
- Baker Hughes Co/Merger↓(OPPORTUNITY)◆
Chart Industries financials filed enabling Nasdaq registration (BKR stock/notes), near-term close post-July 2025 deal boosts energy services scale
- Peapack-Gladstone Financial/Redemption↓(OPPORTUNITY)◆
Clean $100M notes redemption March 2 strengthens capital, positive sentiment for financial stability play
- Dorchester Minerals/Compliance↓(OPPORTUNITY)◆
Nasdaq issue closed Feb 27 post-Sturrock appointment, removes overhang for royalty MLP investor entry
- Bioxytran Inc/Trial Data↓(OPPORTUNITY)◆
90% Day-5 clearance high dose (p=0.001) + safety supports advancement despite mixed endpoint, biotech antiviral upside
- XOMA Royalty Corp/Buyback↓(OPPORTUNITY)◆
$16M repurchase of 648k shares reduces OS to 11.9M, accretive to EPS with $133M cash buffer
Sector Themes(6)
- Capital Allocation Surge◆
4/7 filings show returns/refinancing (XOMA $16M buyback -5% OS, Peapack $100M redeem, Targa $1.5B issue, Baker M&A financials); avg materiality 8.3/10 implies strong shareholder focus vs reinvestment, bullish for yields
- Governance Resolutions◆
2/7 address board/committee issues (Dorchester Nasdaq fix post-death, Peapack director committees), neutral sentiment but reduces delist risk in energy/MLPs
- Mixed Clinical/Portfolio Updates◆
Biotech-adjacent (XOMA/Bioxytran) dominate non-energy with FY2025 receipts ~$49-50M (XOMA) and 90% viral clearance (Bioxytran Day5), mixed sentiment avg 8.5/10 materiality flags catalyst-driven volatility
- M&A and Debt Activity in Energy◆
Energy trio (Baker/Targa/Dorchester) 100% positive/neutral progress (merger financials, $1.5B notes, compliance); no YoY declines, positions sector for capex amid stable ops
- Forward Catalyst Clustering◆
XOMA drives 2026 events (Ph2b/3 data, reg decisions, launches) vs Peapack March 2 redemption; builds Q1-Q2 calendar absent from pure energy peers
- No Broad Margin/Trend Declines◆
Limited PoP data shows XOMA G&A +$1M but offset by receipts; energy filings lack compression (0/3 reported), outperforms hypothetical sector avg
Watch List(8)
Monitor outcome/legal costs impact on G&A, ongoing breach claim over TREMFYA IP [Ongoing]
Phase 2b/3 PAH data expected 2026, key for portfolio milestone upside [2026]
EMA/Japan regulatory filings for cHI/FAP, potential approvals [2026]
Confirm execution and capitalization post-March 2, 2026 event [March 2, 2026]
Post-Ph1b/2a (90% Day5 clearance high dose), watch advancement/regulatory path [Q2 2026+]
Timeline post-financials filing (July 2025 agreement), Nasdaq registration close [Q1-Q2 2026]
Deployment for capex/debt repay/repurchases, impact on energy midstream growth [H1 2026]
Post-compliance fix (Feb 27, 2026), monitor Advisory Committee for further changes [Ongoing]
Filing Analyses(7)
02-03-2026
XOMA Royalty Corp reported preliminary unaudited FY2025 cash receipts from royalties and milestones of ~$49-50M, bolstered by a strong cash position of ~$133M (including $82M unrestricted and $51M restricted) as of December 31, 2025, and repurchased 648,048 common shares for $16M, reducing outstanding shares to 11,888,489 as of February 27, 2026. The company added a total of 24 assets in 2025 through creative deals including royalty acquisitions from KNTE, EPIX, BINV, MURA, LVTX, TSBX, HLVX, TAK, RPRX, and GBIO, enhancing its portfolio of over 100 assets with >$140M milestones received since 2017 and >$2B in future potential. However, G&A expenses rose by $1M due to ongoing litigation against Janssen Biotech over unauthorized use of IP in TREMFYA commercialization, with uncertain outcome and continued legal costs expected.
- ·Commercial portfolio 3Q25 YTD FY26 royalty receipts include $22.5M (Wet AMD/DME/RVO at 0.5% royalty), $8.5M (r/rpLGG at mid-single digit), $2.0M (Niemann-Pick Type C at mid-single digit), $1.3M (Hemophilia-B at mid-single digit), and <$0.5M each for Bacterial Vaginosis, Acute Pain, and FSAD.
- ·Key 2026 catalysts: Seralutinib Phase 2b/3 data (PAH), ersodetug regulatory decisions (EMA, Japan; cHI/FAP), REC-4881 Phase 1/2 data, product launches for ersodetug (THI), volixibat (PSC), rilvegostomig (lung cancer).
- ·Litigation against Janssen asserts breach of contract and unjust enrichment from unauthorized IP use in TREMFYA.
- ·Share price $25.53 as of market close 02/27/2026.
02-03-2026
Peapack-Gladstone Financial Corporation announced its intent to redeem all $100M in aggregate principal amount of its 3.50% Fixed-to-Floating Rate Subordinated Notes due December 22, 2030. The redemption is expected on or about March 2, 2026, at 100% of the principal plus accrued and unpaid interest. The company stated it will remain well capitalized following the redemption.
02-03-2026
Bioxytran, Inc. reported positive Phase 1b/2a results for oral antiviral ProLectin-M in mild-to-moderate COVID-19, with 90% Day-5 viral clearance and clinical improvement at the highest dose (16,800 mg/day) vs 20% placebo (p=0.001). However, the primary endpoint of viral clearance by Day 7 was achieved across all arms due to natural disease resolution, failing to differentiate treatments, while lower doses showed only 20-40% clearance. The drug demonstrated favorable safety with no serious adverse events or discontinuations.
- ·Doses evaluated: 5,600 mg/day, 11,200 mg/day, 16,800 mg/day over 5 days + SOC.
- ·Study conducted in India with RT-PCR-confirmed SARS-CoV-2 patients.
- ·Statistical significance: p=0.001 for highest dose vs placebo on Day-5 viral clearance.
- ·No treatment-related discontinuations; high compliance with regimen.
- ·Filing date: March 02, 2026
02-03-2026
Peapack-Gladstone Financial Corporation filed an 8-K/A amendment to its original December 18, 2025 Form 8-K, disclosing committee assignments for newly appointed directors Diane D’Erasmo and Ellen C. Walsh following a Board meeting on February 26, 2026. Ms. D’Erasmo was appointed to the Risk Committee and Technology Committee, while Ms. Walsh was appointed to the Risk Committee and Compensation Committee, with appointments effective immediately. No other changes to the original filing were made.
- ·Original Form 8-K filed on December 18, 2025
- ·Amendment filed on March 2, 2026
02-03-2026
Baker Hughes Company filed an 8-K on March 2, 2026, reporting on February 27, 2026, and attaching the audited consolidated financial statements of Chart Industries, Inc. as of December 31, 2025 and 2024, and for the three years ended December 31, 2025, in connection with the previously announced merger agreement dated July 28, 2025. The filing includes the consent of Deloitte & Touche LLP as Exhibit 23.1. No specific financial metrics, changes, or performance data are disclosed in the narrative.
- ·Securities registered: Class A Common Stock (BKR, Nasdaq), 5.125% Senior Notes due 2040 (BKR40, Nasdaq)
- ·Principal executive offices: 575 N. Dairy Ashford Rd., Suite 100, Houston, Texas 77079-1121
02-03-2026
Targa Resources Corp. completed a public offering of $750M aggregate principal amount of 4.350% Senior Notes due 2031 and $750M aggregate principal amount of 6.050% Senior Notes due 2056, totaling $1.5B in senior unsecured notes guaranteed by certain subsidiaries. The notes were issued under an indenture dated April 6, 2022, as supplemented on March 2, 2026, with U.S. Bank Trust Company, National Association as trustee. Net proceeds will be used for general corporate purposes, including repaying commercial paper borrowings, other indebtedness, repurchasing securities, capital expenditures, working capital, or subsidiary investments.
- ·Prospectus Supplement dated February 25, 2026, filed February 26, 2026
- ·Base Indenture dated April 6, 2022
02-03-2026
Dorchester Minerals, L.P. resolved a Nasdaq compliance issue arising from the death of independent manager C.W. ('Bill') Russell on October 30, 2025, which reduced the Advisory Committee (audit committee) from three to two members, violating Nasdaq Listing Rules 5615(a)(4)(C) and 5605(c)(2)(A). The Partnership appointed A. Troy Sturrock to the Board and Advisory Committee on February 11, 2026, and Nasdaq confirmed compliance on February 27, 2026, closing the matter. No financial or operational impacts were disclosed.
- ·Nasdaq notified of non-compliance on November 3, 2025; cure period acknowledged on November 10, 2025.
- ·Compliance rules violated: Nasdaq Listing Rules 5615(a)(4)(C) and 5605(c)(2)(A).
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 7 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)